Primary sclerosing cholangitis: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "== " to "==") |
Neil.m.young (talk | contribs) (Text replacement - " ==" to "==") |
||
| Line 1: | Line 1: | ||
==Background | ==Background == | ||
*Autoimmune Dz typically seen in young men | *Autoimmune Dz typically seen in young men | ||
*Progressive inflammation and fibrosis of intra/extra hepatic bile ducts | *Progressive inflammation and fibrosis of intra/extra hepatic bile ducts | ||
| Line 6: | Line 6: | ||
*Prevalence is 1 to 6 per 100,000 in the U.S | *Prevalence is 1 to 6 per 100,000 in the U.S | ||
==Clinical Features | ==Clinical Features == | ||
*Generally asymptomatic but can present with fatigue, [[abdominal pain]], [[jaundice]], cholangitis, puritis, weight loss, or [[fever]] | *Generally asymptomatic but can present with fatigue, [[abdominal pain]], [[jaundice]], cholangitis, puritis, weight loss, or [[fever]] | ||
*Mean age at presentation: 30-40 | *Mean age at presentation: 30-40 | ||
| Line 20: | Line 20: | ||
*Liver biopsy typically shows pericholangitis and periductual fibrosis but is often not diagnostic in early disease | *Liver biopsy typically shows pericholangitis and periductual fibrosis but is often not diagnostic in early disease | ||
==Treatment | ==Treatment == | ||
*High dose Ursodeoxycholic acid (UDCA), 25-30mg/kg/day | *High dose Ursodeoxycholic acid (UDCA), 25-30mg/kg/day | ||
**May improve liver chemistries but does not slow disease progression and may actually hasten development of portal HTN | **May improve liver chemistries but does not slow disease progression and may actually hasten development of portal HTN | ||
| Line 26: | Line 26: | ||
*Liver Transplant should be offered to those with advanced liver disease or repeated bouts of cholangitis (disease can recur after transplantation) | *Liver Transplant should be offered to those with advanced liver disease or repeated bouts of cholangitis (disease can recur after transplantation) | ||
==Disposition | ==Disposition == | ||
*Annual Screening for colon cancer in patients with concomitant [[ulcerative colitis]] | *Annual Screening for colon cancer in patients with concomitant [[ulcerative colitis]] | ||
==See Also | ==See Also == | ||
==References== | ==References== | ||
Revision as of 18:04, 6 July 2016
Background
- Autoimmune Dz typically seen in young men
- Progressive inflammation and fibrosis of intra/extra hepatic bile ducts
- Most (80%) cases are associated with inflammatory bowel dz, typically ulcerative colitis, 10% of patients with ulcerative colitis have PSC
- Increased risk of colon CA in patients with Ulcerative colitis and PSC (more than UC alone) Increased risk of cholangiocarcinoma
- Prevalence is 1 to 6 per 100,000 in the U.S
Clinical Features
- Generally asymptomatic but can present with fatigue, abdominal pain, jaundice, cholangitis, puritis, weight loss, or fever
- Mean age at presentation: 30-40
Differential Diagnosis
Diagnosis
- Alkaline phosphatase is usually elevated with mild elevations in aminotransferases
- Bilirubin is typically normal, except when common hepatic duct or common bile duct is involved in late stages of disease
- Perinuclear antineutrophil cytoplasmic antibody (pANCA) positive in 2/3rds of cases
- Cholangiography
- Diagnosis made by ERCP or MRCP, which demonstrates strictures or beading of the intrahepatic or extrahepatic bile ducts
- Liver biopsy typically shows pericholangitis and periductual fibrosis but is often not diagnostic in early disease
Treatment
- High dose Ursodeoxycholic acid (UDCA), 25-30mg/kg/day
- May improve liver chemistries but does not slow disease progression and may actually hasten development of portal HTN
- Periodic dilation of strictures via ERCP or percutaneous route
- Liver Transplant should be offered to those with advanced liver disease or repeated bouts of cholangitis (disease can recur after transplantation)
Disposition
- Annual Screening for colon cancer in patients with concomitant ulcerative colitis
See Also
References
- Current Clinical Medicine, 2nd edition by Cleveland Clinic